NGL Fine-Chem Limited (NSE:NGLFINE)

Market Cap	8.48B
Revenue (ttm)	3.68B
Net Income (ttm)	211.24M
Shares Out	n/a
EPS (ttm)	34.19
PE Ratio	40.17
Forward PE	n/a
Dividend	3.50 (0.26%)
Ex-Dividend Date	Aug 12, 2025

Volume	4,104
Average Volume	2,525
Open	1,415.00
Previous Close	1,367.60
Day's Range	1,404.30 - 1,435.90
52-Week Range	957.00 - 2,777.95
Beta	0.70
RSI	83.66
Earnings Date	May 12, 2025

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, f...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1981
• Employees: 682
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NGLFINE

Financial Performance

In 2024, NGL Fine-Chem's revenue was 3.68 billion, an increase of 8.73% compared to the previous year's 3.39 billion. Earnings were 211.24 million, a decrease of -48.87%.